- Home
- BA vs GILD Comparison
BA vs GILD Comparison
Compare BA & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BA
- GILD
- Stock Information
- Founded
- BA 1916
- GILD 1987
- Country
- BA United States
- GILD United States
- Employees
- BA N/A
- GILD N/A
- Industry
- BA Aerospace
- GILD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BA Industrials
- GILD Health Care
- Exchange
- BA Nasdaq
- GILD Nasdaq
- Market Cap
- BA 129.6B
- GILD 131.5B
- IPO Year
- BA N/A
- GILD 1992
- Fundamental
- Price
- BA $163.51
- GILD $104.53
- Analyst Decision
- BA Buy
- GILD Buy
- Analyst Count
- BA 19
- GILD 27
- Target Price
- BA $198.00
- GILD $105.32
- AVG Volume (30 Days)
- BA 11.4M
- GILD 10.2M
- Earning Date
- BA 04-23-2025
- GILD 04-24-2025
- Dividend Yield
- BA N/A
- GILD 3.02%
- EPS Growth
- BA N/A
- GILD N/A
- EPS
- BA N/A
- GILD 0.38
- Revenue
- BA $66,517,000,000.00
- GILD $28,754,000,000.00
- Revenue This Year
- BA $31.42
- GILD $1.80
- Revenue Next Year
- BA $16.03
- GILD $3.83
- P/E Ratio
- BA N/A
- GILD $275.08
- Revenue Growth
- BA N/A
- GILD 6.04
- 52 Week Low
- BA $128.88
- GILD $62.07
- 52 Week High
- BA $196.95
- GILD $119.96
- Technical
- Relative Strength Index (RSI)
- BA 48.54
- GILD 43.48
- Support Level
- BA $153.54
- GILD $97.32
- Resistance Level
- BA $162.55
- GILD $107.18
- Average True Range (ATR)
- BA 8.51
- GILD 3.94
- MACD
- BA 0.43
- GILD -0.45
- Stochastic Oscillator
- BA 70.30
- GILD 41.37
About BA Boeing Company (The)
Boeing is a major aerospace and defense firm. It operates in three segments: commercial airplanes; defense, space, and security; and global services. Boeing's commercial airplanes segment competes with Airbus in the production of aircraft that can carry more than 130 passengers. Boeing's defense, space, and security segment competes with defense contractors such as Lockheed and Northrop to create military aircraft, satellites, and weaponry. Global services provides aftermarket support to airlines.
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).